A Case Study on First-In-Human High-Cumulative-Dose Allogeneic Mesenchymal Stem Cell therapy in Multiple Myeloma | Chapter 2 | New Visions in Medicine and Medical Science Vol. 3

 This case reports the results obtained from a relapsed Multiple myeloma (MM) patient treated with high- cumulative-dose allogeneic Mesenchymal stem cells (MSCs).  MM is a highly malignant cancer characterized by the proliferation and accumulation of monoclonal plasma cells in the bone marrow along with end-organ damage due to the underlying disorder. The plasma cells proliferate in the bone marrow and infiltrate the kidney and other organs can result in extensive skeletal destruction, renal failure, anemia, hypercalcemia, and recurrent infections. Despite the remarkable progress in the treatment of MM with the availability of novel agents and hematopoietic cell transplantations (HCTs), an overwhelming majority of patients relapse, and the disease is generally considered incurable. Here we report a case of a 57-year-old male with relapsed MM previously treated with standard of care therapies including high-dose chemotherapy, radiotherapy, and autologous HCT. Based on our previous success with mesenchymal stem cell (MSC)-based therapy and its favorable safety profile, allogeneic MSC infusions were offered as a treatment option. A daily dose of 5.0 × 10 8 MSCs was slowly administered intravenously for about one and a half hours to the patient for ten consecutive days. Three months after the treatment, his laboratory results had returned to within normal ranges, and an MRI showed complete resolution of the lesions. In this study, we showed that a significantly more intensive intervention with respect to both the individual MSCs dose and the frequency of dose administration is an effective treatment strategy for MM. There were no significant adverse effects after administration of MSCs during the course of treatment and follow-up. The patient has since been cancer-free and no longer suffers from osteoporosis, which is usually a life-long complication for patients with MM. This first-in-human study showed that a high cumulative dose of MSCs is a safe and curative treatment for MM.

Author(s) Details:

Sebo Gene Wang,
Top IVF USA, Hacienda Heights, CA, USA.

Nicholas C Hsu,
Top IVF USA, Hacienda Heights, CA, USA.

Sebo Michelle Wang,
Loma Linda University School of Medicine, Loma Linda, CA, USA.

Ming Chu Hsu,
Top IVF USA, Hacienda Heights, CA, USA.

Fu Nan Wang,
Top IVF USA, Hacienda Heights, CA, USA and Stem Cell Life Science Corp., New Taipei City, Taiwan.

Please see the link here: https://stm.bookpi.org/NVMMS-V3/article/view/13949

Multiple Myeloma: A Recent Update | Chapter 3 | Advancement and New Understanding in Medical Science Vol. 1

We present one such case, where the patient manifested with gross enlargement of the mandible, along with lesions in the lower limbs. A monoclonal gammopathy is often a cause for concern, since it signifies an underlying hematological malignancy. Several systemic diseases initially present with various oral manifestations. Investigation of these oral symptoms may at times lead to the diagnosis of grave underlying life-threatening conditions. A 72-year-old male patient presents to the department with a 10-month history of swelling in the mandible. The swelling had gradually increased in size over time with progressive loss of teeth. These lesions were the initial manifestation and on further investigations the patient was diagnosed with multiple myeloma. Osteolytic lesions including oral and maxillofacial lesions need to be examined carefully, both radiologically and pathologically, to identify cases of multiple myeloma.

Author(s) Details:

Divya Vinayachandran,
Department of Oral Medicine and Radiology, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

Sibyl Siluvai,
Department of Public Health Dentistry, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

V. Kalaivani,
Department of Periodontology, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

Prashanthi Gurram,
Department of Oral and Maxillofacial Surgery, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

Lakshmi Rathan A. C.,
Department of Oral and Maxillofacial Surgery, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

Suresh Mitthra,
SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology, Kattankulathur-603203, Chennai, Tamil Nadu, India.

Please see the link here: https://stm.bookpi.org/ANUMS-V1/article/view/13000